| 21.72 -0.17 (-0.78%) | 10-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.16 |
1-year : | 31.75 |
| Resists | First : | 24.96 |
Second : | 27.19 |
| Pivot price | 22.78 |
|||
| Supports | First : | 21.37 | Second : | 17.78 |
| MAs | MA(5) : | 21.95 |
MA(20) : | 23.07 |
| MA(100) : | 24.4 |
MA(250) : | 24.67  |
|
| MACD | MACD : | -1.1 |
Signal : | -1 |
| %K %D | K(14,3) : | 9.8 |
D(3) : | 11.4 |
| RSI | RSI(14): 35.5 |
|||
| 52-week | High : | 33.63 | Low : | 18.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PRPO ] has closed above bottom band by 13.6%. Bollinger Bands are 42.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 22.57 - 22.68 | 22.68 - 22.77 |
| Low: | 21.42 - 21.57 | 21.57 - 21.69 |
| Close: | 21.51 - 21.74 | 21.74 - 21.92 |
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Mon, 12 Oct 2026
Precipio: Management Dreams Big, Institutions Have A Toe In (NASDAQ:PRPO) - Seeking Alpha
Thu, 08 Oct 2026
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - Eastern Progress
Mon, 05 Oct 2026
PRPO Forecast — Price Target — Prediction for 2027 - TradingView
Sun, 20 Sep 2026
Precipio Inc. (PRPO) Edges Higher to $26.46 as Shares Consolidate Below Resistance - Monthly Profile - https://www.dars.gov.et/
Sat, 19 Sep 2026
Precipio Inc. stock gains on Q2 2026 revenue growth and path to profitability - ad-hoc-news.de
Fri, 18 Sep 2026
Precipio Q2 2026 Earnings Call: Complete Transcript - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 12.6 (%) |
| Held by Institutions | 17.7 (%) |
| Shares Short | 69 (K) |
| Shares Short P.Month | 61 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.25 |
| Profit Margin | -4.5 % |
| Operating Margin | -8.6 % |
| Return on Assets (ttm) | -4.9 % |
| Return on Equity (ttm) | -9 % |
| Qtrly Rev. Growth | 24.2 % |
| Gross Profit (p.s.) | 6.7 |
| Sales Per Share | 15.19 |
| EBITDA (p.s.) | -0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -34.48 |
| PEG Ratio | 0 |
| Price to Book value | 2.63 |
| Price to Sales | 1.42 |
| Price to Cash Flow | 35.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|